Categories
Business

Altria (MO) Q1 2021 earnings beat

A Philip Morris Marlboro cigarette burns in an ashtray for this arranged photo in Tiskilwa, Ill. On Wednesday, July 12, 2017.

Daniel Acker | Bloomberg | Getty Images

Altria’s earnings declined in the first quarter as sales fell below estimates and cigarette shipments continued to decline.

The parent company of Marlboro Cigarettes has turned its business away from traditional tobacco products and announced it will acquire the remaining 20% ​​stake in On, a nicotine pouch product.

The company’s stock fell 1.1% in late morning trading.

The company reported for the first quarter, versus Wall Street expectations, based on an analyst survey by Refinitiv:

  • Earnings per share: $ 1.07 adjusted versus $ 1.05 expected
  • Revenue: $ 4.88 billion excluding excise taxes versus $ 4.98 billion expected

Net income declined from $ 1.55 billion, or 83 cents per share last year, to $ 1.42 billion, or 77 cents per share.

Excluding items, Altria earned $ 1.07 per share, beating the analysts surveyed by Refinitiv who expected it to be $ 1.05 per share.

Revenue decreased 5.1% from $ 6.36 billion a year ago to $ 6.04 billion. However, after excise taxes, sales came in at $ 4.88 billion, falling short of what analysts had expected to be $ 4.98 billion.

Total cigarette shipments to wholesalers decreased 12% year over year. However, Altria estimates that cigarette industry shipments were down 2% in the quarter, unchanged from last year’s levels.

Altria again lowered the value of its Juul Vaping brand, this time trading its value around $ 200 million. The company said the fair value of its stake, which it acquired for $ 12.8 billion in December 2018, was $ 1.5 billion at the end of March.

Although the overall vaping category is up 24% year over year, Juul’s retail share is down 6% year over year to 33% of the category, according to the company.

“Against a challenging comparison, our tobacco businesses performed well in the first quarter and we made further progress in developing our non-combustible portfolio,” said CEO Billy Gifford.

Gifford also attributed part of that success to the trends the pandemic brought with it when people were able to smoke more easily at home throughout the day.

“You also have the compensation, you have the government incentives that just came out and we’ll see how consumers feel about when their mobility has increased and what other areas of discretionary spending they could use those incentives for,” added he added a conference call.

Altria and other tobacco companies could face a tougher regulatory environment. On Thursday, the Food and Drug Administration, which regulates tobacco products in the United States, announced a ban on menthol-flavored cigarettes. Menthol cigarettes were often used disproportionately by colored people. The vast majority of black smokers consume menthol cigarettes, and black men have the highest rate of lung cancer deaths in the United States

Altria has a 26% share of the menthol market, which accounts for about a third of all cigarettes sold in the United States. According to a recent report by Bernstein analyst Callum Elliott, around 17% of Altria’s cigarette volume falls into this category.

In addition, the Biden government announced last week that it was considering putting nicotine levels in cigarettes.

All of these potential changes are in the very early stages and are likely to be questioned by the industry.

Altria previously sent a letter to the FDA asking it to make it known that nicotine, the addictive component of cigarettes, does not cause cancer. The company said this would help smokers switch to potentially less risky, non-flammable options, such as: B. their heated tobacco stick Iqos and the nicotine pouch On.

The full publication of the results can be found here.

Categories
Health

Altria asks FDA to unfold the phrase that nicotine does not trigger most cancers

A Marlboro cigarette.

Daniel Acker | Bloomberg | Getty Images

Marlboro’s parent, Altria, has asked the Food and Drug Administration to help spread the word that nicotine doesn’t cause cancer.

CNBC received a copy of a letter Altria sent to the FDA on Thursday asking the agency to spread the word about nicotine as part of a proposed publicity campaign about the risks of tobacco use.

“We received the letter and we will respond directly to the company,” FDA spokeswoman Alison Hunt told CNBC in an email.

Altria was not immediately available to comment on the matter.

In the February 25 letter signed by Paige C. Magness, senior vice president of Regulatory Affairs, Altria cited government studies on misperceptions about nicotine. It was said that eliminating such misperceptions would help traditional smokers switch to non-flammable methods of using nicotine, which may be less risky than products containing smoke.

Bloomberg News first reported the letter Thursday.

While the vast majority of Altria’s revenue comes from the sale of cigarettes and cigars, the company is also involved in vaping firm Juul and the nicotine pouch brand On! Involves and markets IQOS, a smokeless tobacco product that heats tobacco instead of burning it in the United States

There are at least 60 carcinogens in cigarette smoke, but these newer products deliver nicotine without the smoke.

As the regulator of Altria, the FDA can determine what claims it can make of its products. The FDA has allowed Altria to market IQOS in a way that would reduce the exposure of users to harmful chemicals than cigarette smoke.

Nicotine is the addicting ingredient to tobacco and it can have other negative health effects. In its report, Bloomberg said studies have shown that nicotine can affect brain development and birth outcomes, and in large doses acts as an agricultural poison.

Categories
Business

Altria mentioned cigarette business shipments flattened in 2020

Marlboro cigarettes, a product of Philip Morris International

Daniel Acker | Bloomberg | Getty Images

After years of accelerating smoking decline, tobacco giant Altria announced a trend reversal as U.S. cigarette volumes remained unchanged year over year across the industry.

However, the company declined to predict how things would play out in 2021, as it is unclear whether the factors that contributed to this trend would continue.

The pandemic brought more people into their homes, giving smokers more opportunities to take a break from their hectic days and glow more often, especially given the overall higher levels of stress and anxiety due to the economy and health crisis. Employees who worked from home were no longer in a smoke-free office, and consumers generally had more disposable income from restrictions on other forms of entertainment such as restaurants and bars, movie theaters, and travel.

The trend was more pronounced in Altria’s own store. The Marlboro maker’s total cigarette shipping volume declined 0.4% from 2019 and rose 3.1% in the fourth quarter. For comparison: Altria’s cigarette volume decreased by 7.3% from 2018 to 2019.

Altria said it is paying close attention to trends that could affect future cigarette sales.

“Looking ahead, we expect the volume trends in the cigarette industry in 2021 to be driven most by home smoker practices, unemployment rates, tax incentives, cross-category movements, timing and breadth of COVID-19 use – Vaccines and consumer purchasing behavior following vaccine will be affected, “Altria said on a conference call on revenue.

With the expected decline in smoking, Altria has invested in alternatives to cigarettes such as the heated tobacco product iQos and nicotine pouches.

Altria shares closed Thursday at $ 42.65, up 1.98%. The stock is down nearly 15% over the past year for a market value of $ 79.26 billion.

For the fourth quarter, the company reported net income of $ 1.92 billion, or $ 1.03 per share, compared to a loss of $ 1.81 billion a year ago. Excluding items, Altria earned 99 cents per share, which was below analyst estimates. Revenue was better than expected, increasing to $ 6.3 billion from $ 6 billion a year ago.

For 2021, after adjustments, the company expects earnings of $ 4.49 to $ 4.62 per share.